In two big pharmaceutical deals announced Monday, a U.S. cancer drug company passed to Japanese hands and a Pennsylvania company consolidated psychiatric facilities.

, makers of Tarceva among others, for $4 billion in cash in a bid to expand its cancer drug business worldwide.

,  the biggest operator of owned or leased freestanding psychiatric inpatient facilities, for about $2 billion in cash to help strengthen its behavioral services unit and grow its overall business.